The role of BRAF mutations in primary melanoma growth rate and survival

British Journal of Dermatology

Volumn 173, Issue 1, 2015, Pages 76-82

  Mar, V J ^a,b,c   Liu, W ^a   Devitt, B ^d   Wong, S Q ^c   Dobrovic, A ^e   McArthur, G A ^c   Wolfe, R ^b   Kelly, J W ^a  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BRAF PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; CORRELATIONAL STUDY; CUTANEOUS MELANOMA; FEMALE; FOLLOW UP; GENE MUTATION; GROWTH RATE; HUMAN; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MELANOMA GROWTH RATE; MELANOMA SPECIFIC SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; WILD TYPE; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MELANOMA; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RISK FACTOR; SKIN TUMOR;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; SKIN NEOPLASMS;

EID: 84948716195     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13756     Document Type: Article

References (36)

1. Mar VJ, Wong SQ, Logan A, et al,. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma. Pigment Cell Melanoma Res 2014; 27: 1117-25.
2. Devitt B, Liu W, Salemi R, et al,. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011; 24: 666-72.
3. Balch CM, Gershenwald JE, Soong SJ, et al,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
4. Thompson JF, Soong SJ, Balch CM, et al,. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011; 29: 2199-205.
5. Long GV, Menzies AM, Nagrial AM, et al,. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-46.
6. Mann GJ, Pupo GM, Campain AE, et al,. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 2013; 133: 509-17.
7. Si L, Kong Y, Xu X, et al,. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012; 48: 94-100.
8. 600) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol 2012; 19: 4314-21.
9. Nagore E, Requena C, Traves V, et al,. Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol 2014; 70: 858-62.
10. Edlundh-Rose E, Egyházi S, Omholt K, et al,. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16: 471-8.
11. Akslen LA, Angelini S, Straume O, et al,. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 2005; 125: 312-17.
12. Shinozaki M, Fujimoto A, Morton DL, et al,. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004; 10: 1753-7.
13. Ellerhorst JA, Greene VR, Ekmekcioglu S, et al,. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011; 17: 229-35.
14. Houben R, Becker JC, Kappel A, et al,. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004; 3: 6.
15. Kumar R, Angelini S, Czene K, et al,. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003; 9: 3362-8.
16. Maldonado JL, Fridlyand J, Patel H, et al,. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95: 1878-90.
17. Liu W, Kelly JW, Trivett M, et al,. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 2007; 127: 900-5.
18. Liu W, McArthur GA, Trivett M, et al,. Correlation of subjective self-reported melanoma growth rate with objective tumor proliferation markers. Arch Dermatol 2008; 144: 555-6.
19. Grob JJ, Richard MA, Gouvernet J, et al,. The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study. Int J Cancer 2002; 102: 34-8.
20. Liu W, Dowling JP, Murray WK, et al,. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006; 142: 1551-8.
21. Nagore E, Hacker E, Martorell-Calatayud A, et al,. Prevalence of BRAF and NRAS mutations in fast-growing melanomas. Pigment Cell Melanoma Res 2013; 26: 429-31.
22. Martorell-Calatayud A, Nagore E, Botella-Estrada R, et al,. Defining fast-growing melanomas: reappraisal of epidemiological, clinical, and histological features. Melanoma Res 2011; 21: 131-8.
23. Tejera-Vaquerizo A, Nagore E, Herrera-Acosta E, et al,. Prediction of sentinel lymph node positivity by growth rate of cutaneous melanoma. Arch Dermatol 2012; 148: 577-84.
24. Tejera-Vaquerizo A, Lopez-Navarro N, Alcaide-Martin A, et al,. Correlation of the growth rate of melanoma with the temporal appearance of metastasis. J Eur Acad Dermatol Venereol 2011; 25: 366-7.
25. Richter A, Grieu F, Carrello A, et al,. A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep 2013; 3: 1659.
26. Nagore E, Martorell-Calatayud A, Botella-Estrada R, et al,. Growth rate as an independent prognostic factor in localized invasive cutaneous melanoma. J Eur Acad Dermatol Venereol 2011; 25: 618-20.
27. Tejera-Vaquerizo A, Barrera-Vigo MV, Lõpez-Navarro N, Herrera-Ceballos E,. Growth rate as a prognostic factor in localized invasive cutaneous melanoma. J Eur Acad Dermatol Venereol 2010; 24: 147-54.
28. Concato J, Peduzzi P, Holford TR, et al,. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 1995; 48: 1495-501.
29. Whiteman DC, Baade PD, Olsen CM,. More people die from thin melanomas (≤1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Invest Dermatol 2015; 135: 1190-3.
30. Menzies AM, Haydu LE, Visintin L, et al,. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242-9.
31. Bucheit AD, Syklawer E, Jakob JA, et al,. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 2013; 119: 3821-9.
32. Lin MJ, Mar V, McLean C, et al,. An objective measure of growth rate using partial biopsy specimens of melanomas that were initially misdiagnosed. J Am Acad Dermatol 2014; 71: 691-7.
33. Ekedahl H, Cirenajwis H, Harbst K, et al,. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol 2013; 169: 1049-55.
34. Bennett DC,. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 2008; 21: 27-38.
35. Gray-Schopfer VC, Cheong SC, Chong H, et al,. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 2006; 95: 496-505.
36. Curtin JA, Fridlyand J, Kageshita T, et al,. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.